CareDx Inc CDNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
-
CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
-
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
-
CareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
-
CareDx to Participate in Upcoming Investor Conferences
-
CareDx Announces Dismissal of 2021 Qui Tam Suit
-
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
Trading Information
- Previous Close Price
- $29.11
- Day Range
- $28.11–29.25
- 52-Week Range
- $10.96–30.00
- Bid/Ask
- $28.00 / $30.20
- Shares Outstanding
- 51.66M
- Market Cap
- $1.47B
- Volume/Avg
- 665,778 / 840,314
Key Statistics
- Price/Earnings (Normalized)
- 51.73
- Price/Sales
- 3.62
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 5.96%
Company Profile
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 765
- Website
- https://www.caredx.com
Valuation
|
Metric
|
CDNA
|
|---|---|
Price/Earnings (Normalized) | 51.73 |
Price/Book Value | 4.63 |
Price/Sales | 3.62 |
Price/Cash Flow | 28.28 |
Price/Earnings
CDNA
Financial Strength
|
Metric
|
CDNA
|
|---|---|
Quick Ratio | 2.93 |
Current Ratio | 3.40 |
Interest Coverage | — |
Quick Ratio
CDNA
Profitability
|
Metric
|
CDNA
|
|---|---|
Return on Assets (Normalized) | 6.95% |
Return on Equity (Normalized) | 9.32% |
Return on Invested Capital (Normalized) | 6.75% |
Return on Assets
CDNA
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|Nb$!^FL> | LOCK|qL | $196B | |||
| Danaher Corp
DHR
| LOCK|CB?RWpN | LOCK|CL | $141B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|lJL#HhQ | LOCK|CN& | $44B | |||
| Agilent Technologies Inc
A
| LOCK|&YZ$#wD> | LOCK|H# | $38B | |||
| Waters Corp
WAT
| LOCK|&c$C#$ | LOCK|z#X | $37B | |||
| IQVIA Holdings Inc
IQV
| LOCK|Pp?p?Y | LOCK|<f?Cg | $35B | |||
| Illumina Inc
ILMN
| LOCK|&K>YY<h | LOCK|Gt&?# | $29B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|R<BKL$Cf | LOCK|?<<F@ | $26B | |||
| Quest Diagnostics Inc
DGX
| LOCK|!?X^MT | LOCK|^&#q@ | $23B | |||
| Labcorp Holdings Inc
LH
| LOCK|FF#NF$@! | LOCK|T<hws | $23B |
United States